Literature DB >> 22909196

'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.

Jorge Duconge, Gualberto Ruaño.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22909196      PMCID： PMC3505752          DOI： 10.2217/pgs.12.75

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  20 in total

Review 1.  ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.

Authors:  David R Holmes; Gregory J Dehmer; Sanjay Kaul; Dana Leifer; Patrick T O'Gara; C Michael Stein
Journal:  J Am Coll Cardiol       Date:  2010-07-20       Impact factor: 24.094

2.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

Authors:  G Ruaño; J W Goethe; C Caley; S Woolley; T R Holford; M Kocherla; A Windemuth; J de Leon
Journal:  Mol Psychiatry       Date:  2007-01-02       Impact factor: 15.992

3.  Pharmacogenetics in Europe: barriers and opportunities.

Authors:  D Gurwitz; E Zika; M M Hopkins; S Gaisser; D Ibarreta
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

Review 4.  Aspirin and clopidogrel resistance: an emerging clinical entity.

Authors:  Thomas H Wang; Deepak L Bhatt; Eric J Topol
Journal:  Eur Heart J       Date:  2005-12-19       Impact factor: 29.983

5.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

6.  Mechanisms of statin-induced myalgia assessed by physiogenomic associations.

Authors:  Gualberto Ruaño; Andreas Windemuth; Alan H B Wu; John P Kane; Mary J Malloy; Clive R Pullinger; Mohan Kocherla; Kali Bogaard; Bruce R Gordon; Theodore R Holford; Ankur Gupta; Richard L Seip; Paul D Thompson
Journal:  Atherosclerosis       Date:  2011-07-20       Impact factor: 5.162

7.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

8.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

9.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

10.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07
View more
  2 in total

1.  Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.

Authors:  Carmelo Orengo-Mercado; Bianca Nieves; Lizbeth López; Nabila Vallés-Ortiz; Jessicca Y Renta; Pedro J Santiago-Borrero; Carmen L Cadilla; Jorge Duconge
Journal:  J Pharmacogenomics Pharmacoproteomics       Date:  2013-03-27

2.  Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.

Authors:  Rachel Dalton; Joshua D Brown; Julio D Duarte
Journal:  Clin Transl Sci       Date:  2021-05-05       Impact factor: 4.689
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.